c-Triadem:一种受约束,可解释的深度学习模型,用于识别阿尔茨海默病中的新生物标志物
Sherlyn Jemimah1, Ferial Abuhantash1, Aamna AlShehhi1
1Department of Biomedical Engineering and Biotechnology, Khalifa University, Abu Dhabi, United Arab Emirates.
PloS one
|April 14, 2025
概括
一个新的深度学习模型,c-Triadem,准确地识别出阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 的基于血液的生物标志物. 这种方法通过分析遗传和临床数据来增强早期诊断,改善患者的治疗结果.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 人工智能的人工智能
背景情况:
- 早期诊断阿尔茨海默病 (AD) 对于有效管理至关重要,但受到当前生物标志物的限制.
- 现有的AD和轻度认知障碍 (MCI) 的诊断方法往往缺乏早期检测的敏感性.
- 在神经退行性疾病研究中,开发可访问的基于血液的诊断工具是重要的未满足需求.
研究的目的:
- 介绍c-Triadem,一种新的受约束的三输入深度神经网络模型,用于识别基于血液的阿尔茨海默病生物标志物.
- 使用遗传和临床数据的组合,准确预测疾病状态 (认知正常,MCI或AD).
- 提高早期检测和阿尔茨海默病和相关痴呆症的生物标志物发现.
主要方法:
- 开发了c-Triadem,这是一个集成基因定型,基因表达和临床数据的深度神经网络.
- 训练模型使用来自阿尔茨海默氏症神经成像疾病倡议 (ADNI) 队列的数据.
- 采用了夏普利添加式解释 (SHAP) 来识别关键预测特征并验证模型的稳定性.
主要成果:
- 与之前的模型相比,实现了优越的性能,曲线下的面积 (AUC) 为97%的,精度为89%.
- 确定了特定的遗传标记物 (CASP9,LCK,SDC3 SNPs) 和基因表达 (PINK1,ATG5,UBB,UBC) 对预测具有高度影响.
- 突出了DNA损伤反应和线粒细胞吸收途径在阿尔茨海默氏症病原发生中的作用.
结论:
- c-Triadem在使用血液数据预测MCI和AD方面表现出高准确性,为早期诊断提供了一个有前途的途径.
- 该模型有助于发现与AD相关的基于血液的新型遗传标记物.
- 该方法适用于生物标志物识别和检测在其他神经退行性疾病.
更多相关视频
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.7K
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
910
相关概念视频
Alzheimer's Disease: Overview
328
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
328
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
